» Articles » PMID: 2451692

T Cell Autoreactivity to Insulin in Diabetic and Related Non-diabetic Individuals

Overview
Journal J Immunol
Date 1988 Apr 15
PMID 2451692
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

T cell autoreactivity to insulin in type I diabetic and related non-diabetic individuals was analyzed. Peripheral T lymphocytes from both insulin-treated diabetic and untreated non-diabetic members of four families were found to proliferate in vitro in response to human insulin. T cell autoreactivity to insulin therefore does not appear to be diagnostic of the onset of type I diabetes. Highest T cell responses to human insulin were usually detected in insulin-dependent type I diabetes patients treated with a mixture of beef and pork insulin than with self insulin, the greater the dose of animal insulin the higher the T cell response. The T cell repertoires for self insulin appear to be similar in diabetics and non-diabetics based on their patterns of T cell reactivity to beef insulin, port insulin, human insulin, and various peptide of human insulin. The autoreactive T cells analyzed recognize two conformational epitopes of human insulin formed by interactions between A chain and B chain residues. One epitope is associated with the A chain loop and is present in the A1-A14/B1-B16 peptide, and the other epitope consists mainly of B chain residues located in the A16-A21/B10-B25 peptide. These two epitopes are present in amphipathic alpha-helical regions of insulin. HLA-DR (DR3, DR4, and DR5) and HLA-DQ (DQw2/DQw3) Ag can restrict these T cell responses to human insulin epitopes. The ability to detect insulin-specific autoreactive T cells in healthy non-diabetic individuals supports the hypothesis that autoreactive lymphocytes do not necessarily elicit autoimmune disease if present in an environment in which their activity is immunoregulated.

Citing Articles

The roles of vitamin D and cathelicidin in type 1 diabetes susceptibility.

Cristelo C, Machado A, Sarmento B, Gama F Endocr Connect. 2020; 10(1):R1-R12.

PMID: 33263562 PMC: 7923048. DOI: 10.1530/EC-20-0484.


Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.

Itoh A, Ridgway W Immunotargets Ther. 2017; 6:31-38.

PMID: 28580341 PMC: 5448691. DOI: 10.2147/ITT.S117264.


T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives.

Mallone R, Brezar V, Boitard C Clin Dev Immunol. 2011; 2011:513210.

PMID: 21785617 PMC: 3140193. DOI: 10.1155/2011/513210.


Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes.

Toma A, Laika T, Haddouk S, Luce S, Briand J, Camoin L Diabetes. 2008; 58(2):394-402.

PMID: 19011169 PMC: 2628613. DOI: 10.2337/db08-0599.


Replenishing Peripheral CD4(+) Regulatory T Cells: A Possible Immune-Intervention Strategy in Type 1 Diabetes?.

Sia C Rev Diabet Stud. 2007; 3(3):102-7.

PMID: 17487333 PMC: 1783587. DOI: 10.1900/RDS.2006.3.102.